LRT Capital Management LLC Has $615,000 Stake in Repligen Co. (NASDAQ:RGEN)

LRT Capital Management LLC grew its position in Repligen Co. (NASDAQ:RGEN) by 6.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,274 shares of the biotechnology company’s stock after acquiring an additional 276 shares during the period. LRT Capital Management LLC’s holdings in Repligen were worth $615,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Clark & Stuart Inc acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $202,000. Moody National Bank Trust Division increased its holdings in shares of Repligen by 10.2% in the fourth quarter. Moody National Bank Trust Division now owns 1,591 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 147 shares during the last quarter. Park Avenue Securities LLC raised its position in shares of Repligen by 24.8% in the fourth quarter. Park Avenue Securities LLC now owns 3,901 shares of the biotechnology company’s stock valued at $561,000 after purchasing an additional 776 shares during the period. Integrated Investment Consultants LLC lifted its stake in shares of Repligen by 6.0% during the 4th quarter. Integrated Investment Consultants LLC now owns 2,360 shares of the biotechnology company’s stock worth $340,000 after buying an additional 134 shares during the last quarter. Finally, Artemis Investment Management LLP boosted its holdings in shares of Repligen by 18.4% during the 4th quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company’s stock worth $22,143,000 after buying an additional 23,905 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on RGEN. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a report on Wednesday, April 16th. JPMorgan Chase & Co. decreased their price objective on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. Finally, TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.25.

Insider Transactions at Repligen

In related news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by insiders.

Repligen Trading Down 3.6%

Shares of Repligen stock opened at $123.24 on Monday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The company has a market capitalization of $6.92 billion, a price-to-earnings ratio of -241.65, a PEG ratio of 4.54 and a beta of 1.21. The firm’s 50-day moving average price is $135.03 and its two-hundred day moving average price is $145.44.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.28 EPS. On average, analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.